BioScrip reports 10.6% growth in home infusion
ELMSFORD, N.Y. – BioScrip reported revenues of $261.7 million for the first quarter of 2015, a 9.4% increase compared to the same period in 2014. It reported a net loss of $15.9 million vs. $25.3 million. Revenues from the home infusion services segment increased to $244.4 million, reflecting 10.6% growth year-over-year, driven by continued strong organic growth. The company also raised $62.5 million in the first quarter through a private placement of convertible preferred stock to Coliseum Capital Management.